indamycin or vancomycin for suspected infection due to Staphylococcus aureus is also recommended by the IDSA.
Infants and Children less than 50 kg
50 to 180 mg/kg/day IV or IM divided every 6 to 8 hours (Max: 2 g/dose); use higher doses for more severe or serious infections. 200 to 225 mg/kg/day IV or IM divided every 4 to 6 hours (Max: 12 g/day) is recommended by The American Academy of Pediatrics (AAP) for severe infections. For community-acquired pneumonia, 150 mg/kg/day IV divided every 8 hours (Max: 6 g/day) for 10 days is recommended by the Infectious Diseases Society of America (IDSA) for infants and children 3 months and older. The IDSA recommends cefotaxime as empiric therapy in hospitalized pediatric patients who are not fully immunized, have life-threatening infections including empyema, and in regions with high levels of penicillin resistant pneumococcal strains. Consideration of combination therapy with a macrolide for suspected atypical pneumonia or with clindamycin or vancomycin for suspected infection due to Staphylococcus aureus is also recommended by the IDSA.
Premature and Term Neonates older than 7 days
50 mg/kg/dose IV or IM every 8 to 12 hours for neonates 2 kg or less and 50 mg/kg/dose IV or IM every 8 hours for neonates more than 2 kg is recommended by the American Academy of Pediatrics (AAP). The FDA-approved labeling recommends 50 mg/kg/dose IV every 8 hours regardless of weight.
Premature and Term Neonates 7 days and younger
50 mg/kg/dose IV or IM every 12 hours.
For the treatment of bacterial meningitis and ventriculitis.
Intravenous dosage
Adults, Adolescents, and Children 50 kg or more
2 g IV every 4 to 6 hours. Recommended duration of therapy is 7 days for N. meningitidis and H. influenzae, 10 to 14 days for S. pneumoniae, 14 to 21 days for S. agalactiae, and 21 days for gram negative bacilli.
Infants, Children, and Adolescents weighing less than 50 kg
225 to 300 mg/kg/day IV divided every 6 to 8 hours (Max: 2 g/dose) is recommended by the Infectious Diseases Society of America (IDSA). The FDA-approved dosage is 180 mg/kg/day IV divided every 4 to 6 hours (Max: 12 g/day). Recommended duration of therapy is 7 days for N. meningitidis and H. influenzae, 10 to 14 days for S. pneumoniae, 14 to 21 days for S. agalactiae, and 21 days for gram negative bacilli.
Neonates 7 to 29 days
50 mg/kg/dose IV every 6 to 8 hours is recommended by Infectious Diseases Society of America (IDSA). The FDA-approved dosage is 50 mg/kg/dose IV every 8 hours. Suggested duration of therapy is 7 days for N. meningitidis and H. influenzae, 10 to 14 days for S. pneumoniae, 14 to 21 days for S. agalactiae, 21 days for gram negative bacilli, and at least 21 days for Listeria monocytogenes.
Neonates 0 to 7 days
50 mg/kg/dose IV every 8 to 12 hours is recommended by Infectious Diseases Society of America (IDSA). The FDA-approved dosage is 50 mg/kg/dose IV every 12 hours. Suggested duration of therapy is 7 days for N. meningitidis and H. influenzae, 10 to 14 days for S. pneumoniae, 14 to 21 days for S. agalactiae, 21 days for gram negative bacilli, and at least 21 days for Listeria monocytogenes.
For the treatment of urinary tract infection (UTI).
Intravenous or Intramuscular dosage
Adults
1 g IV or IM every 12 hours for uncomplicated infections; 1 to 2 g IV or IM every 8 hours for moderate to severe infections, and 2 g IV every 6 to 8 hours for severe infections. The maximum dosage is 12 g/day.
Adolescents and Children weighing 50 kg or more
1 g IV or IM every 12 hours for uncomplicated infections; 1 to 2 g IV or |
